Argen X SE ADR(ARGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 8:30 AM ET (Korea 10/26 21:30)
Full metrics table
| Index | - | P/E | 33.3 | EPS (ttm) | 26.24 | Insider Own | 0.19% | Shs Outstand | 62.9M | Perf Week | 6.66% |
| Market Cap | 54.95B | Forward P/E | 23.05 | EPS next Y | 31.19% | Insider Trans | - | Shs Float | 62.8M | Perf Month | -9.2% |
| Enterprise Value | 49.81B | PEG | 0.67 | EPS next Q | 7.91 | Inst Own | 45.65% | Short Float | 2.15% | Perf Quarter | -1.7% |
| Income | 1.71B | P/S | 10.52 | EPS this Y | 47.67% | Inst Trans | -3.93% | Short Ratio | 3.83 | Perf Half Y | 11.98% |
| Sales | 5.22B | P/B | 6.42 | EPS next 5Y | 34.36% | ROA | 19.92% | Short Interest | 1.35M | Perf YTD | 3.9% |
| Book/sh | 136.01 | P/C | 10.6 | EPS past 3/5Y | - | ROE | 23.62% | 52W High | -18.55% ($1072.75) | Perf Year | 7.58% |
| Cash/sh | 82.43 | P/FCF | 47.55 | Sales past 3/5Y | 116.43% 151.37% | ROIC | 20.27% | 52W Low | 32.01% ($661.85) | Perf 3Y | 83.81% |
| Dividend Est. | - | EV/EBITDA | 32.4 | EPS Y/Y TTM | 30.28% | Gross Margin | 89.49% | Volatility(W/M) | 3.22% 2.92% | Perf 5Y | 198.03% |
| Dividend TTM | - | EV/Sales | 9.54 | Sales Y/Y TTM | 70.57% | Oper. Margin | 28.83% | ATR (14) | 31.65 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.89 | EPS Q/Q | 104.48% | Profit Margin | 32.82% | RSI (14) | 45.95 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.12 | Sales Q/Q | 60.67% | SMA20 | -0.75% ($880.31) | Beta | 0.48 | Target Price | $1162.1 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/10/22 | SMA50 | -8.32% ($953) | Rel Volume | 0.85 | Prev Close | $875.76 |
| Employees | 1863 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -2.33% 5.38% | SMA200 | 2.49% ($852.48) | Avg Volume(3M) | 0.35M | Price | $873.71 |
| IPO | 2017/5/18 | Option/Short | Yes/Yes | Trades | 11080 | Volume | 299,111 | Change | -0.23% |
🧬 Argenx is a global biotech company focused on treating autoimmune diseases. Built on a llama-derived antibody platform, it develops new drugs in the FcRn inhibitor class, expanding its presence in rare autoimmune areas such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded about as much as usual. That is 85% of its average volume.
ARGX makes money exceptionally well
Of every $100 in sales, $28.83 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +47.7% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,305. Peers typically go for $2,305.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +198.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 45.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #4 of 595 in the industry
Based on market cap of $55B.
MRNA#3 Moderna Inc $80B PER - 
ARGX#4 Argen X SE ADR $55B PER 33.3 
RVMD#5 Revolution Medicines Inc $40B PER - 
ONC#6 BeOne Medicines Ltd ADR $39B PER 66.4 
RPRX#7 Royalty Pharma plc $37B PER 34.0 
FAQ
What kind of company is ARGX?
ARGX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARGX?
The market cap of ARGX is approximately $54.9B, ranking 302 within its sector.
What is the P/E ratio of ARGX?
ARGX has a P/E ratio of approximately 33.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ARGX?
ARGX has recorded a 52-week high of $1072.75 and a low of $661.85.
